![The Asian Pacific Association for the Study of the Liver [APASL]](https://www.apasl.info/wp-apasl/wp-content/themes/apasl/images/header/img_apasl_logo.png){kind=logo}
Triple Therapy in 2013 and beyond in Asia
| URL | http://www.ic-hep.com/webcasts/apasl2014/TTanwandee/ |
|---|---|
| Speaker | Dr. Tawesak Tanwandee |
Drug Resistance and Treatment Failure in Asia
| URL | http://www.ic-hep.com/webcasts/apasl2014/MMizokami/ |
|---|---|
| Speaker | Dr. Masashi Mizokami |
Hepatitis C – Current Treatments: What Can We Offer Patients Now?
| URL | http://www.ic-hep.com/webcasts/apasl2014/DRay-Chaudhuri/ |
|---|---|
| Speaker | Domini Ray-Chaudhuri, MD |
Funding, access and infrastructure for new HCV therapies across Asia Pacific
| URL | http://www.ic-hep.com/webcasts/apasl2014/CGore2/ |
|---|---|
| Speaker | Charles Gore, President, WHA |
Public Health strategies to reduce liver disease in the Asia Pacific Region
| URL | http://www.ic-hep.com/webcasts/apasl2014/CGore/ |
|---|---|
| Speaker | Charles Gore, President, WHA |
Optimizing triple therapy, and IFN/RBV free regimens
| URL | http://www.ic-hep.com/webcasts/apasl2014/KChayama/ |
|---|---|
| Speaker | Dr. Kazuaki Chayama |
Hepatitis C virus lifecycle: What are the best drug targets?
| URL | http://www.ic-hep.com/webcasts/apasl2014/MBeard/ |
|---|---|
| Speaker | Dr. Michael Beard |
Direct Acting Antivirals for HCV GT-1 State of Play in 2014
| URL | http://www.ic-hep.com/webcasts/apasl2014/EGane/ |
|---|---|
| Speaker | Dr. Ed Gane |
Hepatitis C Direct Acting Antivirals for Genotypes 2/3: State of Play 2014
| URL | http://www.ic-hep.com/webcasts/apasl2014/CStedman/ |
|---|---|
| Speaker | Dr. Catherine Stedman |
Host genomics and HCV treatment response: IL-28B and beyond
| URL | http://www.ic-hep.com/webcasts/apasl2014/AThompson/ |
|---|---|
| Speaker | Dr. Alexander J. Thompson |